This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Mylan merger with Pfizer's Upjohn raises competition concerns, New Zealand regulator warns

( March 27, 2020, 05:16 GMT | Official Statement) -- MLex Summary: The merger of US-based pharmaceutical company Mylan and Pfizer subsidiary Upjohn is continuing to raise regulatory concerns in New Zealand, with the competition watchdog today suggesting that it feared the deal would substantially lessen competition due to unilateral effects for the supply of several medicines. In a Statement of Issues released today, the New Zealand Commerce Commission said it required no further information from the companies, but it continued to test whether the merged entity would have the ability to raise prices and reduce service and quality in the supply of the medicines. The Commerce Commission has maintained the May 11 deadline for a decision. The full statement of the New Zealand Commerce Commission follows; the statement of issues is attached. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections